Cargando…
Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state
Pompe disease is an autosomal recessive, lysosomal glycogen storage disease caused by acid α-glucosidase deficiency. Infantile-onset Pompe disease (IOPD) is the most severe form and is characterized by cardiomyopathy, respiratory distress, hepatomegaly, and skeletal muscle weakness. Untreated, IOPD...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121151/ https://www.ncbi.nlm.nih.gov/pubmed/27896132 http://dx.doi.org/10.1016/j.ymgmr.2016.11.001 |
_version_ | 1782469350658146304 |
---|---|
author | Matsuoka, Takashi Miwa, Yoshiyuki Tajika, Makiko Sawada, Madoka Fujimaki, Koichiro Soga, Takashi Tomita, Hideshi Uemura, Shigeru Nishino, Ichizo Fukuda, Tokiko Sugie, Hideo Kosuga, Motomichi Okuyama, Torayuki Umeda, Yoh |
author_facet | Matsuoka, Takashi Miwa, Yoshiyuki Tajika, Makiko Sawada, Madoka Fujimaki, Koichiro Soga, Takashi Tomita, Hideshi Uemura, Shigeru Nishino, Ichizo Fukuda, Tokiko Sugie, Hideo Kosuga, Motomichi Okuyama, Torayuki Umeda, Yoh |
author_sort | Matsuoka, Takashi |
collection | PubMed |
description | Pompe disease is an autosomal recessive, lysosomal glycogen storage disease caused by acid α-glucosidase deficiency. Infantile-onset Pompe disease (IOPD) is the most severe form and is characterized by cardiomyopathy, respiratory distress, hepatomegaly, and skeletal muscle weakness. Untreated, IOPD generally results in death within the first year of life. Enzyme replacement therapy (ERT) with recombinant human acid alpha glucosidase (rhGAA) has been shown to markedly improve the life expectancy of patients with IOPD. However, the efficacy of ERT in patients with IOPD is affected by the presence of symptoms and cross-reactive immunologic material (CRIM) status. We have treated two siblings with IOPD with ERT at different ages: the first was symptomatic and the second was asymptomatic. The female proband (Patient 1) was diagnosed with IOPD and initiated ERT at 4 months of age. Her younger sister (Patient 2) was diagnosed with IOPD at 10 days of age and initiated ERT at Day 12. Patient 1, now 6 years old, is alive but bedridden, and requires 24-hour invasive ventilation due to gradually progressive muscle weakness. In Patient 2, typical symptoms of IOPD, including cardiac failure, respiratory distress, progressive muscle weakness, hepatomegaly and myopathic facial features were largely absent during the first 12 months of ERT. Her cardiac function and mobility were well-maintained for the first 3 years, and she had normal motor development. However, she developed progressive hearing impairment and muscle weakness after 3 years of ERT. Both siblings have had low anti-rhGAA immunoglobulin G (IgG) antibody titers during ERT and have tolerated the treatment well. These results suggest that initiation of ERT during the pre-symptomatic period can prevent and/or attenuate the progression of IOPD, including cardiomyopathy, respiratory distress, and muscle weakness for first several years of ERT. However, to improve the long-term efficacy of ERT for IOPD, new strategies for ERT for IOPD, e.g. modifying the enzyme to enhance uptake into skeletal muscle and/or to cross the blood brain barrier (BBB), will be required. |
format | Online Article Text |
id | pubmed-5121151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-51211512016-11-28 Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state Matsuoka, Takashi Miwa, Yoshiyuki Tajika, Makiko Sawada, Madoka Fujimaki, Koichiro Soga, Takashi Tomita, Hideshi Uemura, Shigeru Nishino, Ichizo Fukuda, Tokiko Sugie, Hideo Kosuga, Motomichi Okuyama, Torayuki Umeda, Yoh Mol Genet Metab Rep Research Paper Pompe disease is an autosomal recessive, lysosomal glycogen storage disease caused by acid α-glucosidase deficiency. Infantile-onset Pompe disease (IOPD) is the most severe form and is characterized by cardiomyopathy, respiratory distress, hepatomegaly, and skeletal muscle weakness. Untreated, IOPD generally results in death within the first year of life. Enzyme replacement therapy (ERT) with recombinant human acid alpha glucosidase (rhGAA) has been shown to markedly improve the life expectancy of patients with IOPD. However, the efficacy of ERT in patients with IOPD is affected by the presence of symptoms and cross-reactive immunologic material (CRIM) status. We have treated two siblings with IOPD with ERT at different ages: the first was symptomatic and the second was asymptomatic. The female proband (Patient 1) was diagnosed with IOPD and initiated ERT at 4 months of age. Her younger sister (Patient 2) was diagnosed with IOPD at 10 days of age and initiated ERT at Day 12. Patient 1, now 6 years old, is alive but bedridden, and requires 24-hour invasive ventilation due to gradually progressive muscle weakness. In Patient 2, typical symptoms of IOPD, including cardiac failure, respiratory distress, progressive muscle weakness, hepatomegaly and myopathic facial features were largely absent during the first 12 months of ERT. Her cardiac function and mobility were well-maintained for the first 3 years, and she had normal motor development. However, she developed progressive hearing impairment and muscle weakness after 3 years of ERT. Both siblings have had low anti-rhGAA immunoglobulin G (IgG) antibody titers during ERT and have tolerated the treatment well. These results suggest that initiation of ERT during the pre-symptomatic period can prevent and/or attenuate the progression of IOPD, including cardiomyopathy, respiratory distress, and muscle weakness for first several years of ERT. However, to improve the long-term efficacy of ERT for IOPD, new strategies for ERT for IOPD, e.g. modifying the enzyme to enhance uptake into skeletal muscle and/or to cross the blood brain barrier (BBB), will be required. Elsevier 2016-11-18 /pmc/articles/PMC5121151/ /pubmed/27896132 http://dx.doi.org/10.1016/j.ymgmr.2016.11.001 Text en © 2016 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Paper Matsuoka, Takashi Miwa, Yoshiyuki Tajika, Makiko Sawada, Madoka Fujimaki, Koichiro Soga, Takashi Tomita, Hideshi Uemura, Shigeru Nishino, Ichizo Fukuda, Tokiko Sugie, Hideo Kosuga, Motomichi Okuyama, Torayuki Umeda, Yoh Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state |
title | Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state |
title_full | Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state |
title_fullStr | Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state |
title_full_unstemmed | Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state |
title_short | Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state |
title_sort | divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset pompe disease treated in the symptomatic or pre-symptomatic state |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121151/ https://www.ncbi.nlm.nih.gov/pubmed/27896132 http://dx.doi.org/10.1016/j.ymgmr.2016.11.001 |
work_keys_str_mv | AT matsuokatakashi divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT miwayoshiyuki divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT tajikamakiko divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT sawadamadoka divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT fujimakikoichiro divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT sogatakashi divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT tomitahideshi divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT uemurashigeru divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT nishinoichizo divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT fukudatokiko divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT sugiehideo divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT kosugamotomichi divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT okuyamatorayuki divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate AT umedayoh divergentclinicaloutcomesofalphaglucosidaseenzymereplacementtherapyintwosiblingswithinfantileonsetpompediseasetreatedinthesymptomaticorpresymptomaticstate |